Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Aimmune to Participate in Three Upcoming Investor Conferences


Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in three upcoming investor conferences in November and December:

Event: Stifel 2019 Healthcare Conference
Date: Wednesday, November 20, 2019
Presentation Time: 3:00 p.m. Eastern Time
Location: New York, NY

Event: Piper Jaffray 31st Annual Healthcare Conference
Date: Tuesday, December 3, 2019
Presentation Time: 9:30 a.m. Eastern Time
Location: New York, NY

Event: Evercore ISI 2nd Annual HealthCONx Conference
Date: Wednesday, December 4, 2019
Presentation Time: 10:35 a.m. Eastern Time
Location: Boston, MA

A live webcast of each fireside chat will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. Replays will be available following each webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for potentially life-threatening food allergies. The Company's Characterized Oral Desensitization ImmunoTherapy (CODITtm) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune's first, investigational, complex biologic product candidate, AR101, is being developed as a treatment to reduce the frequency and severity of adverse events following exposure to peanut. The BLA for AR101 is under review by the FDA, which granted AR101 Breakthrough Therapy Designation in 2015 for the desensitization of peanut-allergic patients 4 to 17 years of age. The European Medicines Agency (EMA) is reviewing Aimmune's Marketing Authorization Application (MAA) for AR101 which Aimmune submitted in June 2019. Aimmune initiated a randomized phase 2 clinical trial of its second investigational, complex biologic product, AR201, for the treatment of egg allergy in August 2019. For more information, please see www.aimmune.com.


These press releases may also interest you

at 07:35
Bentley Statement Regarding Recent News Reports
Bentley Systems, Incorporated , the infrastructure engineering software company, acknowledges the public statement made today by Schneider Electric in response to recent market speculation. Bentley does not publicly comment on market rumors or...

at 07:30
ZTO Express to Hold Annual General Meeting on June 18, 2024
ZTO Express (Cayman) Inc.  ("ZTO" or the "Company"), a leading and fast-growing express delivery company in China, today announced that it will hold its annual general meeting of shareholders ("AGM") on Tuesday, June 18, 2024, at 2 p.m. (local time),...

at 07:13
Baozun Releases 2023 Sustainability Report
Baozun Inc. ("Baozun", the "Company" or the "Group"), a leading brand e-commerce solution provider and digital commerce enabler in China, announced today the release of its 2023 annual sustainability report (the "Sustainability Report"), showcasing...

at 07:05
Executive War College to Address, Clinical Laboratories' and Genetic Testing Firms' Perfect Storm, involving FDA's Proposed LDT Rule, Payers Requiring Z-Codes on Genetic Test Claims, and Revisions to CLIA Regulations
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...

at 07:05
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...

at 07:03
Increased efficiency and added bilingual language support highlight newest updates to RC Mowers' autonomous mower
RC Mowers, a leading manufacturer of robotic mowers, has announced new features to its Autonomous Mowing Robot (AMR)tm, which include a new split plan feature and a bilingual operator interface that allows landscapers to complete jobs more...

More news about Science and technology...


News published on and distributed by: